The global next-generation sequencing (NGS) market is currently witnessing robust growth. Next-generation sequencing, or high-throughput sequencing, refers to the process of determining the sequence of nucleotides in a section of the DNA. It includes procedures such as sequencing by synthesis (SBS), ion semiconductor sequencing, nanopore sequencing and single-molecule real-time (SMRT) sequencing. It is a cost-effective solution that offers precise results with high accuracy and speed. This enables the analysis of millions of DNA molecules simultaneously, which facilitates research in the fields of personalized and genetic medicines, agriculture and animal research, and clinical diagnostics.
The increasing prevalence of chronic medical ailments, such as cancer, along with various technological advancements in the field of medical sciences, is one of the key factors driving the growth of the market. Owing to the widespread adoption of liquid biopsies in cancer diagnostics, there has been a significant increase in the utilization of NGS technologies. These technologies utilize cell-free circulating tumor DNA (ctDNA) as a non-invasive cancer biomarker for real-time cancer monitoring and detection. Furthermore, the increasing adoption of genome mapping programs to predict the development of various diseases is also providing a boost to the market growth. Genetic maps are used for guiding scientists to analyze the genes that are responsible for increasing the prevalence of diabetes, heart diseases, asthma, cancer and psychiatric conditions. Additionally, various technological advancements and integration with the cloud-computing systems for improved data management, are creating a positive impact on the market growth. Other factors, including the declining costs of NGS systems and extensive research and development (R&D) activities in the field of sequencing chemistry, molecular biology and technical engineering, are projected to drive the market further. Looking forward, IMARC Group expects the market to register a CAGR of around 17% during 2020-2025.
Breakup by Sequencing Type:
- Whole Genome Sequencing
- Targeted Resequencing
- Whole Exome Sequencing
- RNA Sequencing
- CHIP Sequencing
- De Novo Sequencing
- Methyl Sequencing
Breakup by Product Type:
- Reagents and Consumables
- Software and Services
Breakup by Technology:
- Sequencing by Synthesis
- Ion Semiconductor Sequencing
- Single-Molecule Real-Time Sequencing
- Nanopore Sequencing
Breakup by Application:
- Drug Discovery and Personalized Medicine
- Genetic Screening
- Agriculture and Animal Research
Breakup by End-User:
- Academic Institutes & Research Centers
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
Breakup by Region:
- North America
- United States
- Asia Pacific
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies, Becton Dickinson and Company, 10x Genomics, BGI Group, Eurofins Scientific, F. Hoffmann-La Roche AG, Illumina Inc., Genewiz, Macrogen, Oxford Nanopore Technologies, Pacific Biosciences, PerkinElmer, Thermo Fisher Scientific, Qiagen N.V., GenapSys Inc., etc.
Key questions answered in this report:
- How has the global next-generation sequencing market performed so far and how will it perform in the coming years?
- What are the key regional markets?
- What is the breakup of the market based on the sequencing type?
- What is the breakup of the market based on the product type?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the end-user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global next-generation sequencing market and who are the key players?
- What is the degree of competition in the industry?